KDR Primary Antibody
|Aliases||FLK1; CD309; VEGFR; VEGFR2|
|Formulation||Ascitic fluid containing 0.03% sodium azide.|
|Immunogen||Purified recombinant extracellular fragment of human KDR (aa20-764) fused with hIgGFc tag expressed in HEK293 cells.|
|Shipping Information||This product will ship in a box containing blue ice at a temperature of 4°C. Learn More|
|ICC (Immunocytochemistry)||1/200 - 1/1000|
|FCM (Flow Cytometry)||1/200 - 1/400|
|WB (Western Blot)||1/500 - 1/2000|
KDR has also been designated as VEFR-2 (Vascular endothelial growth factor receptor 2), CD309 (cluster of differentiation 309) and Flk1 (fetal liver kinase 1). Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. KDR is one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. It functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc.. Mutations of this gene are implicated in infantile capillary hemangiomas.
|References (references)||1. Blood. 2004 Aug 1;104(3):788-94. |
2. FEBS Lett. 2002 Feb 13;512(1-3):107-10.
3. EMBO J. 2001 Jun 1;20(11):2768-78.